Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Evaluating liver steatosis and fibrosis is important for patients with non-alcoholic fatty liver disease. Although liver biopsy and pathological assessment is the gold standard for these conditions, this technique has several disadvantages. The evaluation of steatosis and fibrosis using ultrasound B-mode imaging is qualitative and subjective. The liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) determined using FibroScan are the evidence-based non-invasive measures of liver fibrosis and steatosis, respectively. The LSM and CAP measurements are carried out simultaneously, and the median values of more than ten valid measurements are used to quantify liver fibrosis and steatosis. Here, we demonstrate that the reliability of the LSM depends on the interquartile range to median ratio (IQR/Med), but CAP values do not depend on IQR/Med. In addition, the LSM is affected by inflammation, congestion, and cholestasis in addition to fibrosis, while CAP values are affected by the body mass index in addition to steatosis. We also show that the M probe provides higher LSM values but lower CAP values than the XL probe in the same population. However, there was no statistically significant difference between the diagnostic accuracies of the two probes. These findings are important to understand the reliability of FibroScan measurements and the factors influencing measurement values for all patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 1×
“Liver fibrosis is associated with the prognosis of patients with NAFLD [2,3].”
BackgroundWong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322 · cited 1×
“Liver steatosis and BMI, which affected the CAP, were reported not to affect the LSM after adjusting for the stage of fibrosis [23].”
BackgroundDetermination of reliability criteria for liver stiffness evaluation by transient elastography
Boursier, J., Zarski, J.-P., de Ledinghen, V., Rousselet, M.-C., Sturm, N., Lebail, B., Fouchard-Hubert, I., Gallois, Y., Oberti, F., Bertrais, S., et al. (2013) · Hepatology · doi:10.1002/hep.25993 · Cited by 662 · cited 2×
“Studies have shown that, in patients with ten valid LSMs, the interquartile range to median ratio (IQR/Med) affects the reliability of the LSM results [35,36].”
BackgroundLiver stiffness: a novel parameter for the diagnosis of liver disease
Mueller, S. (2010) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s7394 · Cited by 434
Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, A. W.-H., Chermak, F., Choi, P. C.-L., Merrouche, W., Chu, S. H.-T., Pesque, S., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.331 · Cited by 345 · cited 1×
“3 kPa lower than those measured by the M probe by pairwise examination [28].”
Research works printed but not linked: 66
- Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
- Angulo, 2015, Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients with Nonalcoholic Fatty Liver Disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
- Piccinino, 1986, Complications following percutaneous liver biopsy, J. Hepatol., 2, 165, 10.1016/S0168-8278(86)80075-7 · DOI · Paper page
- Ratziu, 2005, Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084 · DOI · Paper page
- Kuwashiro, 2019, Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study, JGH Open, 4, 497, 10.1002/jgh3.12289 · DOI
- Tincopa, 2020, Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis, Endocrinol. Diabetes Metab., 3, 00177, 10.1002/edm2.177 · DOI
- Yajima, 1983, Ultrasonographical Diagnosis of Fatty Liver: Significance of the Liver-Kidney Contrast, Tohoku J. Exp. Med., 139, 43, 10.1620/tjem.139.43 · DOI · Paper page
- Marshall, 2012, Hepatorenal Index as an Accurate, Simple, and Effective Tool in Screening for Steatosis, Am. J. Roentgenol., 199, 997, 10.2214/AJR.11.6677 · DOI
- Shen, 2006, Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis, World J. Gastroenterol., 12, 1292, 10.3748/wjg.v12.i8.1292 · doi:10.3748/wjg.v12.i8.1292
- Yoneda, M., Honda, Y., Nogami, A., Imajo, K., and Nakajima, A. (2020). Advances in ultrasound elastography for nonalcoholic fatty liver disease. J. Med Ultrason., 1–13. · DOI
- Honda, Y., Yoneda, M., Imajo, K., and Nakajima, A. (2020). Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 21. · DOI
- Hsu, 2019, Magnetic Resonance vs Transient Elastography Analysis of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants, Clin. Gastroenterol. Hepatol., 17, 630, 10.1016/j.cgh.2018.05.059 · DOI · Paper page
- Zhang, 2019, Application of transient elastography in nonalcoholic fatty liver disease, Clin. Mol. Hepatol., 26, 128, 10.3350/cmh.2019.0001n · DOI
- Newsome, 2020, FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study, Lancet Gastroenterol. Hepatol., 5, 362, 10.1016/S2468-1253(19)30383-8 · DOI · Paper page
- Oeda, 2020, Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes, Hepatol. Res., 50, 831, 10.1111/hepr.13508 · DOI
- Eslam, M., Sarin, S.K., Wong, V.W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S.H., Zheng, M.-H., Shiha, G., Yilmaz, Y., and Gani, R. (2020). The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. · DOI · Paper page
- Chan, 2016, Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population, United Eur. Gastroenterol. J., 5, 76, 10.1177/2050640616646528 · DOI · Paper page
- Yoneda, 2007, Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD), Gut, 56, 1330, 10.1136/gut.2007.126417 · DOI · Paper page
- Yoneda, 2008, Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD), Dig. Liver Dis., 40, 371, 10.1016/j.dld.2007.10.019 · DOI · Paper page
- Nobili, 2008, Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis, Hepatology, 48, 442, 10.1002/hep.22376 · DOI · Paper page
- Badea, 2010, Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis, J. Gastrointest. Liver Dis., 19, 53
- Kriener, 2010, Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis, Eur. Radiol., 20, 2390, 10.1007/s00330-010-1820-9 · DOI
- Petta, 2011, Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: The effects of body mass index, Aliment. Pharmacol. Ther., 33, 1350, 10.1111/j.1365-2036.2011.04668.x · DOI · Paper page
- Romen, 2012, Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD, Eur. J. Radiol., 81, e325, 10.1016/j.ejrad.2011.10.029 · DOI · Paper page
- Kumar, 2013, Liver Stiffness Measurements in Patients with Different Stages of Nonalcoholic Fatty Liver Disease: Diagnostic Performance and Clinicopathological Correlation, Dig. Dis. Sci., 58, 265, 10.1007/s10620-012-2306-1 · DOI
- Pathik, 2015, Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India, Ann. Gastroenterol., 28, 281
- Imajo, 2016, Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Than Transient Elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048 · DOI · Paper page
- Eddowes, 2019, Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042 · DOI · Paper page
- Oeda, 2019, Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: A multicenter prospective study, J. Gastroenterol., 55, 428, 10.1007/s00535-019-01635-0 · DOI
- Cardoso, 2020, The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort, Eur. J. Gastroenterol. Hepatol., 32, 231, 10.1097/MEG.0000000000001496 · DOI
- Lucidarme, 2008, Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C, Hepatology, 49, 1083, 10.1002/hep.22748 · DOI · Paper page
- Kettaneh, 2007, Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients, J. Hepatol., 46, 628, 10.1016/j.jhep.2006.11.010 · DOI · Paper page
- Coco, 2007, Transient elastography: A new surrogate marker of liver fibrosis influenced by major changes of transaminases, J. Viral Hepat., 14, 360, 10.1111/j.1365-2893.2006.00811.x · DOI · Paper page
- Arena, 2007, Acute viral hepatitis increases liver stiffness values measured by transient elastography, Hepatology, 47, 380, 10.1002/hep.22007 · DOI · Paper page
- Sagir, 2007, Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage, Hepatology, 47, 592, 10.1002/hep.22056 · DOI · Paper page
- Millonig, 2010, Liver stiffness is directly influenced by central venous pressure, J. Hepatol., 52, 206, 10.1016/j.jhep.2009.11.018 · DOI · Paper page
- Mueller, 2008, 17 Extrahepatic Cholestasis Increases Liver Stiffness (Fibroscan ®) Irrespective of Fibrosis, Gastroenterology, 134, 1718, 10.1016/S0016-5085(08)60013-X · doi:10.1016/s0016-5085(08)60013-x
- Cypierre, 2011, Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool, Amyloid, 18, 19, 10.3109/13506129.2010.543443 · DOI
- Lanzi, 2010, Liver AL amyloidosis as a possible cause of high liver stiffness values, Eur. J. Gastroenterol. Hepatol., 22, 895, 10.1097/MEG.0b013e3283309d5b · DOI
- Mueller, 2015, Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease, Liver Int., 35, 2514, 10.1111/liv.12904 · DOI · Paper page
- Mueller, 2010, Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis, World J. Gastroenterol., 16, 966, 10.3748/wjg.v16.i8.966 · DOI · Paper page
- Mederacke, 2009, Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection, Liver Int., 29, 1500, 10.1111/j.1478-3231.2009.02100.x · DOI · Paper page
- Berzigotti, A., De Gottardi, A., Vukotic, R., Siramolpiwat, S., Abraldes, J.G., García-Pagan, J.C., and Bosch, J. (2013). Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. PLoS ONE, 8. · DOI
- Arena, 2013, Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution, Hepatology, 58, 65, 10.1002/hep.26343 · DOI · Paper page
- Sasso, 2010, Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes, Ultrasound Med. Biol., 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005 · DOI · Paper page
- Shi, 2014, Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy, J. Gastroenterol. Hepatol., 29, 1149, 10.1111/jgh.12519 · DOI · Paper page
- Chan, 2014, Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease, J. Gastroenterol. Hepatol., 29, 1470, 10.1111/jgh.12557 · DOI · Paper page
- Darweesh, 2019, The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients, Eur. J. Gastroenterol. Hepatol., 31, 1010, 10.1097/MEG.0000000000001365 · DOI
- Caussy, 2018, Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis, Hepatology, 67, 1348, 10.1002/hep.29639 · DOI · Paper page
- Myers, 2012, Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography, Liver Int., 32, 902, 10.1111/j.1478-3231.2012.02781.x · DOI · Paper page
- Jung, K.S., Kim, B.K., Kim, S.U., Chon, Y.E., Cheon, K.H., Kim, S.B., Lee, S.H., Ahn, S.S., Park, J.Y., and Kim, D.Y. (2014). Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. PLoS ONE, 9. · DOI
- Wong, 2017, Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter, J. Hepatol., 67, 577, 10.1016/j.jhep.2017.05.005 · DOI
- Sasso, 2012, Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan (®): Validation in chronic hepatitis C, J Viral Hepat., 19, 244, 10.1111/j.1365-2893.2011.01534.x · DOI · Paper page
- Kumar, 2013, Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance?, J. Gastroenterol. Hepatol., 28, 1194, 10.1111/jgh.12134 · DOI · Paper page
- Chon, 2013, Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population, Liver Int., 34, 102, 10.1111/liv.12282 · DOI · Paper page
- Shen, 2014, Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients, World J. Gastroenterol., 20, 4702, 10.3748/wjg.v20.i16.4702 · DOI
- Mi, 2014, Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan®: Validation in Chronic Hepatitis B, Dig. Dis. Sci., 60, 243, 10.1007/s10620-014-3341-x · DOI
- Ratchatasettakul, K., Rattanasiri, S., Promson, K., Sringam, P., and Sobhonslidsuk, A. (2017). The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography. BMC Gastroenterol., 17. · DOI
- Silva, 2018, Effect of Meal Ingestion on Liver Stiffness and Controlled Attenuation Parameter, GE Port. J. Gastroenterol., 26, 99, 10.1159/000488505 · DOI
- Sasso, 2016, Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy, Ultrasound Med. Biol., 42, 92, 10.1016/j.ultrasmedbio.2015.08.008 · DOI
- Myers, 2011, Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology, 55, 199, 10.1002/hep.24624 · DOI · Paper page
- Wong, 2013, Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): Applying the cut-offs of M probe to XL probe, Ann. Hepatol., 12, 402, 10.1016/S1665-2681(19)31341-9 · DOI
- Sporea, 2014, Comparison between the M and XL probes for liver fibrosis assessment by Transient Elastography, Med Ultrason., 16, 119, 10.11152/mu.201.3.2066.162.rs1is2 · DOI
- Caussy, 2020, Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter with the M vs. the XL Probe in Patients with Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging–Proton Density Fat Fraction as the Standard, Clin. Gastroenterol. Hepatol., 18, 1842, 10.1016/j.cgh.2019.11.060 · DOI · Paper page
- Chan, 2018, Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?, J. Gastroenterol. Hepatol., 33, 1787, 10.1111/jgh.14150 · DOI
- Sumida, Y., Yoneda, M., Seko, Y., Ishiba, H., Hara, T., Toyoda, H., Yasuda, S., Kumada, T., Hayashi, H., and Kobayashi, T. (2020). Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics, 10. · doi:10.20944/preprints202007.0314.v1
Cited by
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2306185 · Cited by 314
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312100 · Cited by 286
Invernizzi, P., Carbone, M., Jones, D., Levy, C., Little, N., Wiesel, P., Nevens, F., & the study investigators (2023) · Liver International · doi:10.1111/liv.15596 · Cited by 79
Metadata
- Authors
- Oeda, S., Tanaka, K., Oshima, A., Matsumoto, Y., Sueoka, E., & Takahashi, H.
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2020-11-12
- Volume
- 10
- Issue
- 11
- Pages
- 940
- ISSN
- 2075-4418 (ISSN-L)
- OpenAlex
- W3101045577
- Cited by
- 123
- References
- 6
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. https://app.cochat.ai/papers/10.3390/diagnostics10110940
- The paper
- Oeda, S., Tanaka, K., Oshima, A., Matsumoto, Y., Sueoka, E., & Takahashi, H. (2020). Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics. https://doi.org/10.3390/diagnostics10110940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.